|
Mon, 06/16/2025 - 23:47 |
NKF, Sanford Health Earn UNIVANTS of Healthcare Excellence Award for Transforming CKD Care |
National Kidney... |
|
Thu, 03/20/2025 - 12:53 |
NKFs KidneyCARE Study Celebrates One-Year Milestone, Enrolling Over 1,000 Patients Nationwide |
National Kidney... |
|
Thu, 11/21/2024 - 12:45 |
NKF Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions Publishes Consensus on Transition from Cockcroft Gault Creatinine Clearance to Race-free eGFR Equations |
National Kidney... |
|
Thu, 02/10/2022 - 14:00 |
Johns Hopkins Health System Adopts Race-Free Kidney Function Equation |
Johns Hopkins H... |
|
Tue, 02/08/2022 - 01:54 |
U.S. Laboratories Endorse Race-Free Equations |
National Kidney... |
|
Thu, 08/26/2021 - 10:02 |
Forxiga approved in Japan for the treatment of chronic kidney disease in patients with and without type-2 diabetes |
AstraZeneca |
|
Mon, 08/09/2021 - 11:13 |
Forxiga approved in the EU for the treatment of chronic kidney disease in patients with and without type-2 diabetes |
AstraZeneca |
|
Thu, 06/17/2021 - 00:54 |
Research shows increased risk of chronic kidney disease in people with 'healthy' obesity |
University of B... |
|
Fri, 04/30/2021 - 13:16 |
FDA Approves Treatment for Chronic Kidney Disease |
FDA |
|
Mon, 03/22/2021 - 03:47 |
National Kidney Month: Healthy Living Can Slow Kidney Disease |
Sepsis Alliance |
|
Thu, 02/04/2021 - 12:51 |
NKF and Debbie Allen Partner with Bayer to Launch New Initiative on Risk of CKD in People With T2D |
National Kidney... |
|
Thu, 12/17/2020 - 21:14 |
Update on US regulatory review of roxadustat in anaemia of chronic kidney disease |
AstraZeneca |
|
Tue, 12/08/2020 - 23:40 |
New Survey Shows Education and Communication Gaps in Lupus Nephritis Care |
Lupus Research |
|
Sun, 12/06/2020 - 23:27 |
Survey Shows Education and Communication Gaps in Lupus Nephritis Care |
National Kidney... |
|
Fri, 10/23/2020 - 11:54 |
Drug Study Offers New Hope to Patients with Both Chronic Kidney Disease and Type 2 Diabetes |
National Kidney... |
|
Fri, 10/02/2020 - 11:51 |
Farxiga granted Breakthrough Therapy Designation in US for chronic kidney disease |
AstraZeneca |
|
Wed, 09/30/2020 - 21:13 |
Premera Invests $10 Million in Nonprofit Kidney Care Providers |
Premera Blue Cross |
|
Sun, 09/20/2020 - 21:59 |
New Study Offers Hope for Patients with Diabetes and Advanced Kidney Disease |
National Kidney... |
|
Sun, 08/30/2020 - 02:15 |
Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial |
AstraZeneca |
|
Tue, 07/28/2020 - 10:32 |
Farxiga met all primary and secondary endpoints in groundbreaking Phase III DAPA-CKD trial for the treatment of patients with chronic kidney disease |
AstraZeneca |
|
Fri, 06/05/2020 - 04:02 |
AstraZeneca presents new data across continuum of care from its broad renal portfolio at ERA-EDTA 2020 Virtual Congress |
AstraZeneca |
|
Wed, 05/20/2020 - 00:11 |
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat |
Astellas |
|
Thu, 04/09/2020 - 10:23 |
The National Kidney Foundation Releases Commentary on Hepatitis C Guidelines for Clinicians |
National Kidney... |
|
Mon, 03/30/2020 - 03:10 |
Farxiga Phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease |
AstraZeneca |
|
Wed, 03/25/2020 - 10:59 |
Promising Drug Treatment Study Presented at National Kidney Foundation's Spring Clinical Meetings |
National Kidney... |
